Sivakumaran T, Mileshkin L, Grant P, Na L, et al. Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study. Gynecol Oncol 2020 May 4. pii: S0090-8258(20)31016.
PMID: 32381362